Tailing Biological discloses regulatory status over the past five years, previously received a warning letter due to information disclosure issues.

Log in to the Sina Finance app and search 【Disclosure Requirements】 to view more assessment tiers

Zhejiang Tailin Biotechnology Co., Ltd. (Stock code: 300813; stock abbreviation: Tailin Bio) released an announcement on March 27, disclosing the situation over the past five years in which the company has been subject to regulatory measures or penalties by securities regulatory authorities and stock exchanges. The announcement shows that there have been no instances of penalties against the company over the past five years. However, in 2025, it received a regulatory warning letter issued by the Zhejiang Securities Regulatory Bureau, and the related issues have already been rectified.

The announcement stated that, given that the company plans to proceed with the issuance of convertible corporate bonds to unspecified parties, in order to protect investors’ right to know, it specifically discloses the relevant information. Following a self-examination, the company found that over the past five years there have been no cases in which it was penalized by securities regulatory authorities or stock exchanges.

As for regulatory measures, the company received regulatory warnings only once in 2025. Specifically, on February 21, 2025, the company received from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission the decision titled “Decision on Taking the Measures of Issuing a Warning Letter to Zhejiang Tailin Biotechnology Co., Ltd. and Relevant Persons” ([2025] No. 28). The decision letter pointed out that during an on-site inspection, it was found that the company had issues such as insufficient capacity of certain fund-raised projects, changes to land use for self-built projects, and failure to timely disclose that investment in a joint venture company was suspended.

The Zhejiang Securities Regulatory Bureau believes that the above conduct of the company violates the provisions of Article 3 and Article 5 of the “Administrative Measures for Information Disclosure of Listed Companies.” The then Chairman Ye Dalin and the Financial Controller and Secretary to the Board of Directors Ye Xingyue violated the provisions of Article 4 of the “Administrative Measures for Information Disclosure of Listed Companies.” Pursuant to Article 52 of the “Administrative Measures for Information Disclosure of Listed Companies,” the Zhejiang Securities Regulatory Bureau decided to separately take the supervisory management measures of issuing warning letters to the company, Ye Dalin, and Ye Xingyue, and to record this in the integrity file for the securities and futures market.

Regarding the above issues, Tailin Bio stated that it has completed the rectification. After receiving the decision letter, the company immediately organized all directors, supervisors, senior management, and relevant personnel to analyze and discuss the issues, and to implement rectification measures. The rectification measures include strengthening the study of laws and regulations, improving awareness of standardized operations, strengthening the establishment and implementation of internal control systems, arranging relevant personnel to attend training, and increasing the intensity of supervision and inspections in key areas. At present, the company has organized relevant personnel to study laws and regulations such as the “Administrative Measures for Information Disclosure of Listed Companies” and the “Rules Governing the Listing of Stocks on the Shenzhen Stock Exchange’s ChiNext Board,” as well as the company’s internal management rules. It has also formulated effective rectification measures. The relevant issues have been completed and rectified, and going forward it will continue to operate in a long-term, standardized manner.

Apart from the above circumstances, over the past five years, the company has not had any other instances in which securities regulatory authorities and stock exchanges took regulatory measures against it.

Click to view the full text of the announcement>>

Statement: The market involves risk; investment should be done with caution. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are discrepancies, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.

Vast amounts of information and precise interpretation—right on the Sina Finance app

Responsible editor: Xiaolang KuaiBao